JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman LLC is pursuing a class action lawsuit against Jasper Therapeutics, Inc. for alleged securities law violations.Summary
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Jasper Therapeutics, Inc. (NASDAQ: JSPR) and its officers. The lawsuit alleges that the company made false and misleading statements between November 30, 2023, and July 3, 2025, regarding its controls and procedures for third-party manufacturers, potentially impacting clinical trial results and the commercial prospects of its products, including briquilimab. Specifically, the complaint claims Jasper failed to ensure its manufacturers adhered to cGMP regulations, increasing the risk of flawed study results and potential cost-reduction measures. Investors who experienced losses during the specified “Class Period” are encouraged to join the case and may request to be appointed as lead plaintiff by November 18, 2025. The firm represents investors on a contingency fee basis, meaning costs are only recovered if the case is successful.
(Source：NewMediaWire)